Abstract
The race for effective treatments against coronavirus disease 2019 has reminded pediatricians of historical delays that children have faced in drug development and clinical trials. In response to this, legislation and regulations including the Best Pharmaceuticals for Children Act (US, 2002), Pediatric Research Equity Act (US, 2003), and Pediatric Regulation (European Union, 2007) spurred the conduct of pediatric trials through a combination of incentives and requirements for pharmaceutical companies to increase pediatric drug approvals and evidence supporting treatments for children.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
